NCT06732180 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 21, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Parkinson Disease

Interventions

DRUG

GT-02287

Dose of 13.5 mg/kg/day (plus/minus 2 mg/kg/day based on body weight) to be administered orally once a day for 90 days. Dosage form: powder in sachet (200 mg of GT-02287 per sachet) for reconstitution with a suspending agent

Trial Locations (7)

Unknown

RECRUITING

St Vincent's Hospital Sydney, Darlinghurst

RECRUITING

Southern Neurology, Kogarah

RECRUITING

Westmead Hospital, Westmead

RECRUITING

Princess Alexandra Hospital, Woolloongabba

RECRUITING

CMAX, Adelaide

RECRUITING

Alfred Health, Melbourne

RECRUITING

Royal Melbourne Hospital, Parkville